Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulmonx Corporation, a leading provider of minimally invasive lung disease treatments, announced on June 1, 2026, that it granted equity awards to 17 new employees who were hired in the first half of the year. The awards were issued under the 2025 Inducement Plan and approved by the Compensation Committee of the Company’s Board of Directors. This move, in compliance with Nasdaq Listing Rule 5635(c)(4), was intended to attract and retain top talent. Each award is contingent upon the Inducement Plan's terms and the corresponding grant agreements.